We are thrilled to announce the appointment of the new board member Tom Duensing to Sarcura’s board of Advisors

Aug. 2024 / Company
Daniela Buchmayr

With over 25 years of experience  in life science tools and biopharmaceutical firms, Tom brings a wealth of expertise that spans the entire company lifecycle—from building startups to navigating acquisitions, and leading product development in a multinational corporate setting.

His deep knowledge in technology and strategic positioning, coupled with his proven track record of driving innovation, will be invaluable as we embark on the exciting journey of bringing our groundbreaking platform to market, a platform poised to revolutionize the scalability of cell therapies and transform patient outcomes.

“I am excited and energized to join the advisory board at Sarcura, and to help this amazing team bring it’s transformative technology to the market.”

Tom Duensing, Ph.D.

LinkedIn

Most recently, he served as Head of Product Development for the LPS Division at Sartorius, where he was accountable for a global team of 300 scientists and engineers developing innovative products for cell based and biochemical analysis.

Prior to that Tom was Chief Technology Office for IntelliCyt, where he led the development of the company’s technical strategy and innovation execution for their novel high throughput flow cytometry platform from startup through acquisition.

Over the years Thomas has held leadership positions in life science tools and biopharmaceutical firms focusing on strategy development and scaling technology into thriving businesses. He earned his Ph.D. in Microbiology and Immunology from Creighton University School of Medicine.

“With the clinical success of cell therapies now clearly demonstrated, it’s time to turn our focus to manufacturing these therapies. Sarcura’s innovative technology brings a miniaturized, automated, reproducible and ultimately scalable process to qualifying cell therapies which will be a significant factor in making cell therapies more accessible to more patients. I’m very much looking forward to helping Sarcura bring this technology to the market.”